1. Home
  2. SLXN vs CERO Comparison

SLXN vs CERO Comparison

Compare SLXN & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • CERO
  • Stock Information
  • Founded
  • SLXN 2008
  • CERO 2017
  • Country
  • SLXN Israel
  • CERO United States
  • Employees
  • SLXN N/A
  • CERO N/A
  • Industry
  • SLXN
  • CERO
  • Sector
  • SLXN
  • CERO
  • Exchange
  • SLXN NYSE
  • CERO Nasdaq
  • Market Cap
  • SLXN 5.0M
  • CERO 8.4M
  • IPO Year
  • SLXN N/A
  • CERO N/A
  • Fundamental
  • Price
  • SLXN $1.08
  • CERO $2.06
  • Analyst Decision
  • SLXN Strong Buy
  • CERO
  • Analyst Count
  • SLXN 1
  • CERO 0
  • Target Price
  • SLXN $9.00
  • CERO N/A
  • AVG Volume (30 Days)
  • SLXN 31.3M
  • CERO 737.7K
  • Earning Date
  • SLXN 02-25-2025
  • CERO 02-24-2025
  • Dividend Yield
  • SLXN N/A
  • CERO N/A
  • EPS Growth
  • SLXN N/A
  • CERO N/A
  • EPS
  • SLXN N/A
  • CERO N/A
  • Revenue
  • SLXN N/A
  • CERO N/A
  • Revenue This Year
  • SLXN N/A
  • CERO N/A
  • Revenue Next Year
  • SLXN N/A
  • CERO N/A
  • P/E Ratio
  • SLXN N/A
  • CERO N/A
  • Revenue Growth
  • SLXN N/A
  • CERO N/A
  • 52 Week Low
  • SLXN $0.21
  • CERO $1.70
  • 52 Week High
  • SLXN $13.56
  • CERO $1,095.00
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • CERO 37.15
  • Support Level
  • SLXN N/A
  • CERO $1.70
  • Resistance Level
  • SLXN N/A
  • CERO $2.22
  • Average True Range (ATR)
  • SLXN 0.00
  • CERO 0.30
  • MACD
  • SLXN 0.00
  • CERO 0.27
  • Stochastic Oscillator
  • SLXN 0.00
  • CERO 24.32

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Share on Social Networks: